A detailed history of American Century Companies Inc transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, American Century Companies Inc holds 63,210 shares of ITOS stock, worth $472,178. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,210
Previous 46,322 36.46%
Holding current value
$472,178
Previous $687,000 6.11%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.09 - $17.97 $170,399 - $303,477
16,888 Added 36.46%
63,210 $645,000
Q2 2024

Aug 07, 2024

BUY
$10.33 - $18.09 $100,376 - $175,780
9,717 Added 26.55%
46,322 $687,000
Q1 2024

May 14, 2024

BUY
$9.89 - $13.64 $96,931 - $133,685
9,801 Added 36.57%
36,605 $499,000
Q4 2023

Feb 13, 2024

BUY
$8.57 - $11.06 $229,710 - $296,452
26,804 New
26,804 $293,000
Q3 2023

Nov 13, 2023

SELL
$10.95 - $14.6 $213,426 - $284,568
-19,491 Reduced 27.43%
51,555 $564,000
Q2 2023

Aug 14, 2023

SELL
$12.93 - $18.05 $507,424 - $708,354
-39,244 Reduced 35.58%
71,046 $940,000
Q1 2023

May 11, 2023

SELL
$13.02 - $22.62 $812,656 - $1.41 Million
-62,416 Reduced 36.14%
110,290 $1.5 Million
Q4 2022

Feb 13, 2023

SELL
$17.77 - $21.6 $884,341 - $1.07 Million
-49,766 Reduced 22.37%
172,706 $3.37 Million
Q3 2022

Nov 14, 2022

BUY
$18.6 - $27.25 $1.06 Million - $1.56 Million
57,252 Added 34.65%
222,472 $4.24 Million
Q2 2022

Aug 12, 2022

BUY
$16.57 - $35.1 $726,180 - $1.54 Million
43,825 Added 36.1%
165,220 $3.4 Million
Q1 2022

May 11, 2022

BUY
$31.92 - $47.45 $2.34 Million - $3.47 Million
73,187 Added 151.82%
121,395 $3.91 Million
Q4 2021

Feb 07, 2022

BUY
$26.23 - $47.86 $1.26 Million - $2.31 Million
48,208 New
48,208 $2.25 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $266M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.